FP 7 Nanoznanosti, nanotehnologije, materijali i nove
proizvodne tehnologije (NMP)
WP 2012
Mr. sc. Smiljka Viki-Topi Ured za znanost i transfer tehnologije Centar za translacijska i klinika istraivanja Medicinskog fakulteta Sveuilita u Zagrebu i Klinikog bolnikog centra Zagreb Zagreb, 5. srpnja, 2011. 1
2
Aktivnosti i zadaci Ureda za znanost i transfer tehnologije Podizanje kapaciteta u dobivanju meunarodnih
projekata Pronalaenje izvora financiranja, pomo oko pisanja
meunarodnih projektnih prijedloga i provedbe projekata
Poticanje znanstvenika Medicinskog fakulteta na prepoznavanje izuma, edukacija o TT, pomo oko zatite IV, eventualne komercijalizacije - suradnja sa sveuilinim Uredom za TT
Napredak i poboljanje znanstvene administracije na dobrobit istraivaa
FP projekti na MEF-u: 6 FP5, 7 FP6, 5 FP7 + OSTEOGROW
MAGISTER
MAGnetIc Scaffolds for in vivo Tissue EngineeRing
Mislav Jeli Mario Josipovi Klinika za ortopediju KBC-a Zagreb i Medicinskog fakulteta Sveuilita u Zagrebu [email protected] 3
Cilj projekta: opisati, istraiti i proizvesti novi oblik bioaktivnog nosaa - kontrola akcije
Mislav Jeli 4
Interdisciplinarni pristup; industrija i
znanost
Mislav Jeli 5
Italija
panjolska Velika Britanija
Njemaka eka
Francuska
vicarska Hrvatska
Rusija Bjelorusija
20 Partnera
10 zemalja
Mislav Jeli 6
Financije
Mislav Jeli 7
8
Prof. Vukievi 9
Projektna ideja (Project sheet) Zato
Sveukupan cilj (odgovor EU komisiji) Specifian cilj (zato ovaj projekt) Koji je problem i kako ga projekt rjeava?
Za koga Ciljana skupina (direktna i indirektna)
Kako Aktivnosti koje e se provesti Glavni koraci projekta Resursi
S kim Partneri Balansirani konzorcij
Gdje Lokacija
Rezultati Output Outcome Impact
10
Prva faza
Kratka prijava, 6 strana State-of-the-art, Beyond state-of -the-art Metodologija i radni plan (radni paketi)
Strategija i plan Pert dijagram, miljokazi
Utjecaj (Impact) Strateki/socioloki Ekonomski Europski/meunarodni
Konzorcij i resursi Partneri Ljudski i financijski
11
Evaluacija 1. Scientific and/or technological excellence (relevant to the topics addressed by the call)
(Threshold 4/5)
Very good outline proposal for the criterion under consideration.
Note: w hen a proposal only partially addresses the topics, this condition will be reflected in the scoring of this criterion
Mark:
4 / 5
2. Potential impact through the development, dissemination and use of project results
(Threshold 3/5)
Very good outline proposal for the criterion under consideration.
Mark:
4/ 5
Other remarks (Threshold 8/10)
Total score:
8 / 10
12
Struktura projekta
13
Radni paketi/ Pert dijagram
Mislav Jeli 14
15
16
17
18
Za mef.hr
19
20
1. Scientific and/or technological excellence (relevant to the topics addressed by the call)
(Threshold 4/5)
The proposal deals with the production and testing of a BMP-6 containing device for fracture repair of long bones, the setting-up of GMP facilities to produce efficiently BMP-6 and a phase I / II clinical trial, which aims to evaluate the device in patients with radial fractures, high tibial wedge osteotomy, cancellous bone repair and osteoporotic disease. The mode of action of BMP-6 is known and been reviewed in relationship to two other well-established BMPs 2 and 7. The proposers have shown that BMP-6 effects are superior to those of BMP-2 and BMP-7 and it can be applied at much lower concentrations - close to 100-fold lower dose - in pre-clinical animal models. Moreover, the Consortium has shown that the BMP-6 can be trapped within an autologous blood clot, the latter being used as a safer, cheaper and effective release device, avoiding possible adverse events caused by bovine collagen sponges used in the delivery of BMP-2 and -7.
Mark:
4,5 / 5
2. Quality and efficiency of the implementation and the management
(Threshold 3/5)
Management structures are described in a clear and appropriate manner. Consortium participants have the necessary expertise and complementary experience in the key areas of product development and clinical evaluation, as reflected in the submission. However, this could be further strengthened by including an External Advisory Board, a point that the Consortium will wish to consider, to assist in achieving its objectives. Of particular note, the Consortium comprises 11 partners from 7 European countries 6 of which are located in Eastern Europe. Resources are correctly allocated and appropriately justified.
Mark:
4 / 5
3. Potential impact through the development, dissemination and use of project results
(Threshold 3/5)
The proposal meets the impact of the call. If the outcome is successful, the project will deliver:
Strategic / social /economic impacts e.g. real cost reduction for the treatment of elderly patients with fractures and increase their quality of life.
Scientific impact and Impact on Standards e.g. OSTEOGROW will address production of BMP6 in large quantities, new tools for the production of GMP grade BMP6, the development of novel bioassays and characterization of binding of BMP-6 to, and release from, blood coagulum specific components
European added value - Considerable SME participation in this project will stimulate innovation and their participation in clinical trials
Dissemination of information and exploitation of the outcome of this project and the related research have been described in an appropriate manner.
Mark:
4 / 5
Other remarks
(Threshold 12/15)
Total score:
12,5 / 15
Uspjean projekt
Dobro napisan
Uspjeno proveden postupak evaluacije
Odgovara natjeaju
Dobar konzorcij
Izvor: Doc.dr.sc. Donatella Verbanac 21
Priprema projekta to je vano?
Znanstvena izvrsnost! Ostalo:
1. to nam treba (oprema, materijali)? 2. Koliko vremena (PM)? 3. Koliko kota (Cijena rada, ostalo)? 4. Kako se to rauna (Cost model)? 5. Podrka, tim
Sami ili uz pomo drugih?
22
Koordinator?
Prednosti: Glavni istraiva , odreuje tijek projekta Reputacija
Nedostaci:
Odgovornost za rezultate svih partnera Zahtjevna administracija Neusporedivo vie posla (a ne toliko vie novca)
23
Pronalaenje partnera
Vai suradnici u Europi, osobni kontakti Nacionalne kontakt osobe (NCP) Mrena stranica Europske komisije za ispunjavanje profila
partnera http://cordis.europa.eu/partners-service/home_en.html
Validacija ideje, pregled uspjenih projekata http://cordis.europa.eu/fp7/projects_en.html
Prijavite se u FP7 bazu evaluatora! https://cordis.europa.eu/emmfp7/
24
http://cordis.europa.eu/partners-service/home_en.htmlhttp://cordis.europa.eu/partners-service/home_en.htmlhttp://cordis.europa.eu/partners-service/home_en.htmlhttp://cordis.europa.eu/partners-service/home_en.htmlhttp://cordis.europa.eu/partners-service/home_en.htmlhttp://cordis.europa.eu/fp7/projects_en.htmlhttp://cordis.europa.eu/fp7/projects_en.htmlhttp://cordis.europa.eu/fp7/projects_en.htmlhttp://cordis.europa.eu/fp7/projects_en.htmlhttps://cordis.europa.eu/emmfp7/
25
HVALA NA PANJI!
PITANJA?
Mr.sc. Smiljka Viki-Topi [email protected]
tel. 4566 972
Ured za znanost i transfer tehnologije Centar za translacijska i klinika istrai vanja
Medicinskog fakulteta Sveuilita u Zagrebu i Klinikog bolnikog centra Zagreb
mailto:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]
